Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) has finalized its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and a warehousing center in Frederick, Maryland, for $122.5 million. The transaction, completed through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.
With this acquisition, Bora Biologics now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites—Rockville, Maryland and San Diego, California—plus a development facility in Zhubei, Taiwan. This strategic expansion establishes a US biologics manufacturing platform that supports sponsors from development through licensed commercial supply. According to Bobby Sheng, Chairman and CEO of Bora Group, regulatory and supply chain dynamics are driving biotech and pharmaceutical companies to seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet this need with an integrated, end-to-end biologics platform spanning drug substance and drug product capabilities.
The Rockville facility adds significant capacity to Bora's network, which now supports more than four active commercial programs, with over 120 completed GMP batches supplying markets including the US, EU, Japan, Canada, and the UK. The platform features fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, all with clean results. The combined platform has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency.
Bora Group plans to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, aiming to offer a seamless, fully integrated development-through-commercial biologics solution. This move positions Bora as a key player in the biologics CDMO market, leveraging its dual-engine model combining CDMO and commercial expertise. For more information about Bora's services and capabilities, visit https://www.bora-corp.com or https://www.boracdmo.com.
The acquisition underscores the growing trend of pharmaceutical companies investing in US-based manufacturing to ensure supply chain resilience and regulatory compliance. By expanding its biologics capacity, Bora is positioned to support the increasing demand for complex biologics and biosimilars, particularly as regulatory scrutiny and geopolitical factors encourage domestic production. This move also enhances Bora's ability to serve global markets while maintaining high-quality standards.
